DR. DONALD WILLIAM KUFE, M.D.
Osteopathic Medicine at Brookline Ave, Boston, MA

6486170, Nov 26, 2002

May 24, 1994

08/248058

Dennis E. Hallahan - Des Plaines IL
Ralph R. Weichselbaum - Chicago IL
Donald W. Kufe - Wellesley MA

Arch Development Corporation - Chicago IL

A61K 3144

514297, 4352402, 4351731, 514747, 514263, 514291, 514169

A signaling pathway is identified that involves the activation of phospholipase A2 and protein kinase C in human cells, which in turn confers x-ray induction of the tumor necrosis factor (TNF) gene. Inhibition of phospholipase A2 abolishes radiation-mediated arachidonate production, as well as the subsequent activation of protein kinase C and TNF gene expression. These phospholipase A2 inhibitors may be used to ameliorate the adverse-effects of radiotherapy associated with TNF production.

5770581, Jun 23, 1998

Jun 7, 1995

8/474445

Ralph R. Weichselbaum - Chicago IL
Dennis E. Hallahan - Park Ridge IL
Vikas P. Sukhatme - Chicago IL
Donald W. Kufe - Wellesley MA

Arch Development Corp. - Chicago IL
Dana-Farber Cancer Institute - Boston MA

A61K 4800

514 44

The present invention provides a DNA molecule comprising a radiation responsive enhancer-promoter operatively linked to an encoding region that encodes at least one polypeptide. An encoding region can comprise a single encoding sequence for a polypeptide or two or more encoding sequences encoding DNA binding, activation or repression domains of a transcription factor. Processes for regulating polypeptide expression and inhibiting tumor growth using such DNA molecules are also provided.

4963484, Oct 16, 1990

Jan 29, 1988

7/149831

Donald W. Kufe - Wellesley MA

Dana-Farber Cancer Institute, Inc. - MA

C12D 2100, C12N 120, C12N 1500, C07H 1512

435 693

A carbohydrate-free polypeptide coded for by a human DNA sequence of 309 nucleotides is immunologically reactive with monoclonal antibody against the human DF3 breast carcinoma-associated antigen. The nucleotide sequence is also useful as a probe to reveal restriction fragment length polymorphisms in human DNA.

5571797, Nov 5, 1996

May 11, 1994

8/241863

Tsuneya Ohno - Boston MA
Ralph R. Weichselbaum - Chicago IL
Donald W. Kufe - Wellesley MA

Arch Development Corporation - Chicago IL

A61K 4800, A61K 5100

514 44

The present invention provides a method for delivering ionizing radiation to specific tissues, resulting in the activation of a DNA molecule comprising a radiation responsive enhancer-promoter operatively linked to an encoding region that encodes at least one polypeptide. The radiation source may be will generally be in the form of a radionuclide, capable of gamma or beta emissions. Processes for regulating polypeptide expression and inhibiting tumor growth using such DNA molecules are also provided.

2005014, Jul 7, 2005

Sep 21, 2004

10/946365

Dennis Hallahan - Park Ridge IL, US
Ralph Weichselbaum - Chicago IL, US
Donald Kufe - Wellesley MA, US
Gregory Sibley - Chapel Hill NC, US
Bernard Roizman - Chicago IL, US

A61K048/00, C12N015/869

424093200, 435456000

The present invention is directed to novel methods of enhancing the effectiveness of DNA damaging agents by exposing cells to viruses prior to or during exposure to the damaging agent. In certain embodiments of the invention, the DNA damaging agent is ionizing radiation, the virus is an adenovirus, and the increase in cell killing is synergistic when compared to radiation alone.

7247297, Jul 24, 2007

Sep 16, 2002

10/244705

Ralph R. Weichselbaum - Chicago IL, US
Donald W. Kufe - Wellesley MA, US

The University of Chicago - Chicago IL
Dana-Farber Cancer Institute - Boston MA

A61K 48/00, A01N 63/00

424 932

The present invention provides for improved vectors for use in gene therapy. Utilizing the cancer specific DF3/MUC1 promoter to drive a replication essential gene, vectors are made conditionally replication-competent, permitting wider infection and expression of tumor cells. In addition, therapeutic genes and adjunct therapies further increase anti-tumor efficacy.

8614186, Dec 24, 2013

May 27, 2010

12/789127

Donald W. Kufe - Wellesley MA, US
Surender Kharbanda - Natick MA, US

Dana-Farber Cancer Institute, Inc. - Boston MA
Genus Oncology, LLC. - Chicago IL

A61K 38/00, A61P 29/00

514 122

The invention provides for peptides from the MUC1 cytoplasmic domain and methods of use therefor. These peptides can inhibit MUC1 oligomerization, inhibit the interaction of MUC1 with NF-κB or a STAT, and block inflammatory response mediated by NF-κB or STAT signaling.

2008010, May 8, 2008

Jul 27, 2007

11/829687

Donald Kufe - Wellesley MA, US

Dana-Farber Cancer Institute, Inc. - Boston MA

A61K 38/00, C12Q 1/48, G06G 7/48, A61K 31/195, A61P 43/00, C12N 5/06, A61K 39/395

424172100, 435015000, 703011000, 435375000, 514002000, 514567000

The present disclosure provides methods of identifying and making compounds and pharmaceutical compositions thereof that inhibit the interaction between MUC1 and Abl. The invention also provides in vivo, in vitro, and ex vivo methods of inhibiting such an interaction. Also featured are in vitro and in vivo methods of stimulating the Abl-dependent apoptotic pathway in cells expressing MUC1. In such methods, the compounds, compositions, and methods described herein are generally useful in the treatment of various cancers. The disclosure also provides methods for inhibiting Abl, and such methods, and compounds and compositions for use in the methods are generally useful for the treatment of cancers, inflammatory conditions, atherosclerotic lesions, and neurologic disorders.

2012004, Feb 23, 2012

Feb 14, 2011

13/026858

Donald W. Kufe - Wellesley MA, US
Surender Kharbanda - Natick MA, US

A61K 9/127, A61K 38/08, A61K 38/03, A61K 9/14, A61K 9/50, A61P 35/00, A61P 35/02, C12N 5/09, A61K 9/00, B82Y 5/00

424450, 435375, 514 193, 514 11, 424400, 424499, 977906, 977788

The present invention is directed to improved compositions for cellular delivery of peptides. Using segments of only 3-5 positively-charged residues, one can effectively transfer peptides, including therapeutic peptides, into cells. Also provided are modified peptides such as those include stapled and cyclized peptide technology, as well as peptoids/peptidomimetics.